Pharmacological Treatment of Atrial Fibrillation: Mechanisms of Action and Efficacy of Class III Drugs

By  

Current Medicinal Chemistry, Vol. 13, Iss. 14, 2006-06 ,pp. : 1635-1653

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of Atrial Fibrillation and Flutter: Focus on Oral Dofetilide, a New Selective Class III Antiarrhythmic Agent

By  

Heart Drug, Vol. 1, Iss. 6, 2002-02 ,pp. : 320-331

Karger

Access to resources Recommend Favorite

Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation

By Torp-Pedersen C.   Brendorp B.   Køber L.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2695-2704

Informa Healthcare

Access to resources Recommend Favorite

Antiarrhythmic drugs for atrial fibrillation

By Marinelli Alessandro   Capucci Alessandro  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 8, 2011-06 ,pp. : 1201-1215

Informa Healthcare

Access to resources Recommend Favorite

Sales of drugs for atrial fibrillation are projected to grow from $790 million in 2008 to $6.1 billion by 2018

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 594, 2010-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite